ABSTRACT
Ninety-five eyes of 91 patients with myopia from -1.00 to -6.00 D (mean -3.40 D, +/- 1.2) were treated with an ExciMed UV2OOLA 193-nanometer excimer laser (Summit Technology, Inc, Waltham, Mass) (with version 5.5 software) with a 5-millimeter ablation zone. At 6 months, 67 eyes (70%) were within +/- 0.50 D, 84 eyes (88%) were within +/- 1.00 D, and 94 eyes (99%) were within +/- 2.00 D. There was an average overcorrection of +0.25 D which had decreased to +0.18 D by 9 months. Best spectacle corrected visual acuity was 6/6 or better in 88 eyes (94%) and six eyes (6%) had a corrected visual acuity of 6/9. Fifty percent of eyes had slight astigmatism (mean 0.68 D, range 0.25 to 2.00 D) and this reduced to 0.33D (0.02 > p > 0.01) at 6 months.
Subject(s)
Cornea/surgery , Laser Therapy , Myopia/surgery , Adult , Aged , Female , Follow-Up Studies , Humans , Laser Therapy/adverse effects , Male , Middle Aged , Myopia/physiopathology , Treatment Outcome , Visual AcuityABSTRACT
Clobetasone butyrate, a new corticosteroid with a high topical activity, has been compared with prednisolone phosphate and a placebo in the treatment of inflammation following cataract extraction. These 2 steroids were more effective in relieving postoperative inflammation than placebo (P less than 0.05), though no obvious clinical differences between the 2 compounds emerged from this investigation. However, a single-blind comparative study against betamethasone phosphate in patients suspected of having steroid-induced glaucoma showed that, while betamethasone phosphate significantly raised intraocular pressure, clobetasone butyrate had only a minimal effect, and this difference was statistically significant (P less than 0.02).
